Hereditary nonpolyposis colorectal cancer explained

Hereditary nonpolyposis colorectal cancer

Hereditary nonpolyposis colorectal cancer (HNPCC) is a hereditary predisposition to colon cancer.

HNPCC includes (and was once synonymous with)[1] Lynch syndrome, an autosomal dominant genetic condition that is associated with a high risk of colon cancer, endometrial cancer (second most common), ovary, stomach, small intestine, hepatobiliary tract, upper urinary tract, brain, and skin.[2] The increased risk for these cancers is due to inherited genetic mutations that impair DNA mismatch repair. It is a type of cancer syndrome.

Other HNPCC conditions include Lynch-like syndrome, polymerase proofreading-associated polyposis and familial colorectal cancer type X.

Signs and symptoms

Risk of cancer

Lifetime risk and mean age at diagnosis for Lynch syndrome–associated cancers[3]

Type of cancerLifetime risk (%)Mean age at diagnosis (years)
Colorectal52-5844-61
Endometrial25-6048-62
Gastric6-1356
Ovarian4-1242.5
In addition to the types of cancer found in the chart above, it is understood that Lynch syndrome also contributes to an increased risk of small bowel cancer, pancreatic cancer, ureter/renal pelvis cancer, biliary tract cancer, brain cancer, and sebaceous neoplasms. Increased risk of prostate cancer and breast cancer has also been associated with Lynch syndrome, although this relationship is not entirely understood.

Two-thirds of colon cancers occur in the proximal colon and common signs and symptoms include blood in the stool, diarrhea or constipation, and unintended weight loss.[4] The mean age of colorectal cancer diagnosis is 44 for members of families that meet the Amsterdam criteria. The average age of diagnosis of endometrial cancer is about 46 years. Among women with HNPCC who have both colon and endometrial cancer, about half present first with endometrial cancer, making endometrial cancer the most common sentinel cancer in Lynch syndrome.[5] The most common symptom of endometrial cancer is abnormal vaginal bleeding.[6] In HNPCC, the mean age of diagnosis of gastric cancer is 56 years of age with intestinal-type adenocarcinoma being the most commonly reported pathology. HNPCC-associated ovarian cancers have an average age of diagnosis of 42.5 years-old; approximately 30% are diagnosed before age 40.

Significant variation in the rate of cancer has been found depending on the mutation involved.[7] [8] Up to the age of 75 years the risks of different cancers by the mutations are in the table below.

Genecolorectal cancer riskendometrial cancer riskovarian cancer riskupper gastrointestinal (gastric, duodenal, bile duct or pancreatic) cancer riskurinary tract cancers riskprostate cancer riskbrain tumor risk
MLH146%43%10%21%8%17%1%
MSH257%17%10%25%32%5%n.a.
MSH615%46%13%7%11%18%1%
Risk of gynecologic cancer in Lynch syndrome[9] !Gene!Ovarian cancer risk!Endometrial cancer risk
MLH14-24%25-60%
MSH2/EPCAM4-24%25-60%
MSH61-11%16-26%
PMS26% (combined risk)15%

Genetics

Lynch syndrome is inherited in an autosomal dominant fashion.[10] The hallmark of Lynch syndrome is defective DNA mismatch repair, which causes an elevated rate of single nucleotide changes and microsatellite instability, also known as MSI-H (the H is "high"). MSI is identifiable in cancer specimens in the pathology laboratory.[11] Most cases result in changes in the lengths of dinucleotide repeats of the nucleobases cytosine and adenine (sequence: CACACACACA...).[12]

The 4 main genes involved in Lynch syndrome normally encode for proteins that form dimers to function:

  1. MLH1 protein dimerizes with PMS2 protein to form MutLα, which coordinates the binding of other proteins involved with mismatch repair like DNA helicase, single-stranded-DNA binding-protein (RPA), and DNA polymerases.[13] [14]
  2. MSH2 protein dimerizes with MSH6 protein, which identifies mismatches via a sliding clamp model, a protein for scanning for errors.[15] [16]

The impairment of either gene for the protein dimer impairs the protein function.[17] These 4 genes are involved in error correction (mismatch repair), so dysfunction of the genes can lead to the inability to fix DNA replication errors and cause Lynch syndrome.[18] Lynch syndrome is known to be associated with other mutations in genes involved in the DNA mismatch repair pathway:

OMIM nameGenes implicated in HNPCCFrequency of mutations in HNPCC familiesLocusFirst publication
HNPCC1 MSH2/EPCAMapproximately 60%2p22Fishel 1993
HNPCC2 MLH1approximately 30%3p21Papadopoulos 1994[19]
HNPCC5MSH67-10%2p16Miyaki 1997[20]
HNPCC4PMS2relatively infrequent7p22Nicolaides 1994
HNPCC3PMS1case report[21] 2q31-q33Nicolaides 1994
HNPCC6TGFBR2case report[22] 3p22
HNPCC7MLH3disputed[23] 14q24.3

People with MSH6 mutations are more likely to be Amsterdam criteria II-negative.[24] The presentation with MSH6 is slightly different from with MLH1 and MSH2, and the term "MSH6 syndrome" has been used to describe this condition.[25] In one study, the Bethesda guidelines were more sensitive than the Amsterdam Criteria in detecting it.[26]

Up to 39% of families with mutations in a Lynch syndrome gene do not meet the Amsterdam criteria. Therefore, families found to have a deleterious mutation in a Lynch syndrome gene should be considered to have Lynch syndrome regardless of the extent of the family history. This also means that the Amsterdam criteria fail to identify many people who are at risk for Lynch syndrome. Improving the criteria for screening is an active area of research, as detailed in the Screening Strategies section of this article.

Most people with Lynch syndrome inherit the condition from a parent. However, due to incomplete penetrance, variable age of cancer diagnosis, cancer risk reduction, or early death, not all people with an Lynch syndrome gene mutation have a parent who had cancer. Some people develop HNPCC de-novo in a new generation, without inheriting the gene. These people are often only identified after developing an early-life colon cancer. Parents with HNPCC have a 50% chance of passing the genetic mutation on to each child. It is also important to note, that deleterious mutation in one of MMR genes alone is not sufficient to cause cancer, but that rather further mutations in other tumour suppressor genes need to occur.[27]

Diagnosis

A diagnosis of Lynch syndrome is applied to people with a germline DNA mutation in one of the MMR genes (MLH1, MSH2, MSH6, and PMS2) or the EPCAM gene, identified by genetic testing.[28] Candidates for germline genetic testing can be identified by clinical criteria such as the Amsterdam Clinical Criteria and Bethesda Guidelines, or through tumor analysis by immunohistochemistry (IHC), or microsatellite instability (MSI) testing. In the US, professional societies recommend testing every colon cancer for MSI or IHC as screening for Lynch syndrome, but this is not always performed because of cost and resource limitations.[29] Genetic testing is commercially available and consists of a blood test.

Immunohistochemistry

Immunohistochemistry (IHC) is a method that can be used to detect abnormal mismatch repair (MMR) protein expression in tumours that are associated with Lynch syndrome. While it is not diagnostic of a Lynch syndrome, it can play a role in identifying people who should have germline testing.[30] Two methods of implementation of IHC testing includes age-based testing and universal testing for all people.[31] Currently, there is no widespread agreement regarding which screening method should be used. Age-based testing for IHC has been suggested in part due to cost-benefit analyses, whereas universal testing for all people with colorectal cancer ensures people with Lynch Syndrome are not missed. To address the costs, researchers are trying to predict MSI or IHC directly from the way the tumor looks under the microscope, without doing any molecular testing.[29]

Microsatellite instability

Mutations in DNA mismatch repair systems can lead to difficulty transmitting regions within the DNA which contain repeating patterns of two or three nucleotides (microsatellites), otherwise known as microsatellite instability (MSI).[32] MSI is associated with alternate sized repetitive DNA sequences that are not present in the correlated germ line DNA resulting in 15-20% of colorectal cancers.[33] MSI is identified through DNA extraction from both a tumor tissue sample and a normal tissue sample followed by PCR analysis of microsatellite regions. MSI analysis can be used to identify people who may have Lynch syndrome and direct them for further testing. One study noted that one third of MSI colorectal cancers showed a low immunoscore, suggesting that tumor-infiltrating lymphocytes might be a good option for therapy for these patients. High numbers of tumor-infiltrating lymphocytes were related with better survival rates and treatment responses.[34]

Classification

Three major groups of MSI-H (microsatellite instability – MSI) cancers can be recognized by histopathological criteria:

The histopathological criteria are not sensitive enough to detect MSI from histology but researchers are trying to use artificial intelligence to predict MSI from histology.[29]

In addition, HNPCC can be divided into Lynch syndrome I (familial colon cancer) and Lynch syndrome II (HNPCC associated with other cancers of the gastrointestinal tract or reproductive system).[35]

Screening

Genetic counseling and genetic testing are recommended for families that meet the Amsterdam criteria, preferably before the onset of colon cancer.

Colon cancer

Colonoscopies are recommended as a preventative method of surveillance for individuals who have Lynch syndrome, or LS-associated genes. Specifically, it is recommended that colonoscopies begin at ages 20–25 for MLH1 and MSH2 mutation carriers and 35 years for MSH6 and PMS2 mutation carriers.[36] Colonoscopic surveillance should then be performed at a 1-2 year interval for Lynch Syndrome patients.

Endometrial/ovarian cancer

A transvaginal ultrasound with or without endometrial biopsy is recommended annually for ovarian and endometrial cancer screening.[37] For women with Lynch syndrome, a yearly CA-125 blood test can be used to screen for ovarian cancer, however there is limited data on the efficacy of this test in reducing mortality.[38]

Other cancers

There are also strategies for detecting other cancers early or reducing the chances of developing them that people with Lynch syndrome can discuss with their doctor, however their effectiveness is not clear.[39] [40] These options include:

Amsterdam criteria

The following are the Amsterdam criteria in identifying high-risk candidates for molecular genetic testing:[41]

Amsterdam I Criteria (all bullet points must be fulfilled): The Amsterdam I criteria were published in 1990; however, were felt to be insufficiently sensitive.[42]

The Amsterdam II criteria were developed in 1999 and improved the diagnostic sensitivity for Lynch syndrome by including cancers of the endometrium, small bowel, ureter and renal pelvis.[43]

Amsterdam Criteria II (all bullet points must be fulfilled):

The Bethesda criteria were developed in 1997 and later updated in 2004 by the National Cancer Institute to identify persons requiring further testing for Lynch syndrome through MSI. In contrast to the Amsterdam Criteria, the Revised Bethesda Guidelines use pathological data in addition to clinical information to help health care providers identify persons at high risk.

Revised Bethesda Guidelines

If a person meets any 1 of 5 criteria the tumour(s) from the person should be tested for MSI:

  1. Colorectal cancer diagnosed before age 50
  2. Presence of synchronous or metachronous colorectal or other Lynch syndrome associated cancers (e.g. cancers of endometrium, ovary, stomach, small bowel, pancreas, biliary tract, ureter, renal pelvis, brain, sebaceous glands, keratoacanthomas)
  3. Colorectal cancer with MSI-high pathology in a person who is younger than 60 years of age
  4. Colorectal cancer diagnosed in a person with one or more first-degree relative with colorectal cancer or Lynch syndrome associated tumour diagnosed under age 50
  5. Person with colorectal cancer and two or more first- or second-degree relatives with colorectal cancer or Lynch syndrome associated cancer diagnosed at any age.

It is important to note that these clinical criteria can be difficult to use in practice and clinical criteria used alone misses between 12 and 68 percent of Lynch syndrome cases.

Surgery

Prophylactic hysterectomy and salpingo-oophorectomy (removal of the uterus, fallopian tubes, and ovaries to prevent cancer from developing) can be performed before ovarian or endometrial cancer develops.

Treatment

Surgery remains the front-line therapy for Lynch syndrome. Patients with Lynch syndrome who develop colorectal cancer may be treated with either a partial colectomy or total colectomy with ileorectal anastomosis. Due to increased risk of colorectal cancer following partial colectomy and similar quality of life after both surgeries, a total colectomy may be a preferred treatment for Lynch syndrome, especially in younger patients.[44]

There is an ongoing controversy over the benefit of 5-fluorouracil-based adjuvant therapies for Lynch syndrome-related colorectal tumours, particularly those in stages I and II.[45]

Checkpoint blockade with anti-PD-1 therapy is now preferred first line therapy for advanced Microsatellite-Instability–High colorectal cancer.[47]

Epidemiology

Though the exact prevalence of Lynch syndrome-causing mutations in the general population remain unknown, recent studies estimate the prevalence to be 1 in 279 individuals, or 0.35%.[48] [49] Certain populations are known to have a higher prevalence of founder mutations, including, but not limited to, French Canadians, Icelanders, African Americans, and Ashkenazi Jews. Lynch syndrome-causing mutations are found in approximately 3% of all diagnosed colorectal cancers, and 1.8% of all diagnosed endometrial cancers. The average age of diagnosis of cancer in patients with this syndrome is 44 years old, as compared to 64 years old in people without the syndrome.[50]

Terminology

Henry T. Lynch, Professor of Medicine at Creighton University Medical Center, characterized the syndrome in 1966.[51] In his earlier work, he described the disease entity as "cancer family syndrome." The term "Lynch syndrome" was coined in 1984 by other authors; Lynch named the condition HNPCC in 1985. Since then the two terms have been used interchangeably, until later advances in the understanding of the genetics of the disease led to the term HNPCC falling out of favor.[52]

Other sources reserve the term "Lynch syndrome" when there is a known DNA mismatch repair defect, and use the term "familial colorectal cancer type X" when the Amsterdam criteria are met but there is no known DNA mismatch repair defect.[53] The putative "type X" families appear to have a lower overall incidence of cancer and lower risk for non-colorectal cancers than families with documented DNA mismatch repair deficiency.[54] About 35% of people who meet Amsterdam criteria do not have a DNA-mismatch-repair gene mutation.[55]

Complicating matters is the presence of an alternative set of criteria, known as the "Bethesda Guidelines."[56] [57] [58]

Society

There are a number of non-profit organisations providing information and support, including Lynch Syndrome International, AliveAndKickn, Lynch Syndrome UK[59] and Bowel Cancer UK.[60] In the US, National Lynch Syndrome Awareness Day is March 22.[61]

Further reading

Books

External links

Notes and References

  1. Carethers . John M . Stoffel . Elena M . 2015-08-21 . Lynch syndrome and Lynch syndrome mimics: The growing complex landscape of hereditary colon cancer . World Journal of Gastroenterology . 21 . 31 . 9253–9261 . 10.3748/wjg.v21.i31.9253 . 1007-9327 . 4541378 . 26309352 . free .
  2. Kastrinos F, Mukherjee B, Tayob N, Wang F, Sparr J, Raymond VM, Bandipalliam P, Stoffel EM, Gruber SB, Syngal S . 6 . Risk of pancreatic cancer in families with Lynch syndrome . JAMA . 302 . 16 . 1790–5 . October 2009 . 19861671 . 4091624 . 10.1001/jama.2009.1529 .
  3. Web site: Lynch Syndrome. February 22, 2019. DynaMed. November 18, 2019.
  4. Vogel JD, Eskicioglu C, Weiser MR, Feingold DL, Steele SR . The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Treatment of Colon Cancer . Diseases of the Colon and Rectum . 60 . 10 . 999–1017 . October 2017 . 28891842 . 10.1097/DCR.0000000000000926 .
  5. Book: Hoffman, Barbara L. . vanc . Williams Gynecology . Chapter 33: Endometrial Cancer . 2012 . McGraw-Hill Medical . New York . 978-0071716727 . http://www.accessmedicine.com/content.aspx?aID=56712550 . 2nd . 2014-06-23 . 2014-01-04 . https://web.archive.org/web/20140104204142/http://www.accessmedicine.com/content.aspx?aID=56712550 . dead .
  6. Braun MM, Overbeek-Wager EA, Grumbo RJ . Diagnosis and Management of Endometrial Cancer . American Family Physician . 93 . 6 . 468–74 . March 2016 . 26977831 .
  7. Sobocińska. Joanna. Kolenda. Tomasz. Teresiak. Anna. Badziąg-Leśniak. Natalia. Kopczyńska. Magda. Guglas. Kacper. Przybyła. Anna. Filas. Violetta. Bogajewska-Ryłko. Elżbieta. Lamperska. Katarzyna. Mackiewicz. Andrzej. 2020-10-05. Diagnostics of Mutations in MMR/EPCAM Genes and Their Role in the Treatment and Care of Patients with Lynch Syndrome. Diagnostics. 10. 10. 786. 10.3390/diagnostics10100786. 2075-4418. 7600989. 33027913. free.
  8. Møller. Pål. Seppälä. Toni T.. Bernstein. Inge. Holinski-Feder. Elke. Sala. Paulo. Gareth Evans. D.. Lindblom. Annika. Macrae. Finlay. Blanco. Ignacio. Sijmons. Rolf H.. Jeffries. Jacqueline. 2018. Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database. Gut. 67. 7. 1306–1316. 10.1136/gutjnl-2017-314057. 1468-3288. 6031262. 28754778.
  9. Ring. Kari L.. Garcia. Christine. Thomas. Martha H.. Modesitt. Susan C.. 2017. Current and future role of genetic screening in gynecologic malignancies. American Journal of Obstetrics and Gynecology. 217. 5. 512–521. 10.1016/j.ajog.2017.04.011. 1097-6868. 28411145. 29024566.
  10. Web site: Lynch Syndrome . Genetics Home Reference.
  11. http://www.annalsnyas.org/cgi/content/abstract/910/1/62 Pathology of Hereditary Nonpolyposis Colorectal Cancer - JASS 910 (1): 62 - Annals of the New York Academy of Sciences
  12. Oki E, Oda S, Maehara Y, Sugimachi K . Mutated gene-specific phenotypes of dinucleotide repeat instability in human colorectal carcinoma cell lines deficient in DNA mismatch repair . Oncogene . 18 . 12 . 2143–7 . March 1999 . 10321739 . 10.1038/sj.onc.1202583 . free .
  13. Yokoyama T, Takehara K, Sugimoto N, Kaneko K, Fujimoto E, Okazawa-Sakai M, Okame S, Shiroyama Y, Yokoyama T, Teramoto N, Ohsumi S, Saito S, Imai K, Sugano K . 6 . Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature review . BMC Cancer . 18 . 1 . 576 . May 2018 . 29783979 . 5963021 . 10.1186/s12885-018-4489-0 . free .
  14. Peltomäki P . Role of DNA mismatch repair defects in the pathogenesis of human cancer . Journal of Clinical Oncology . 21 . 6 . 1174–9 . March 2003 . 12637487 . 10.1200/JCO.2003.04.060 .
  15. Tamura K, Kaneda M, Futagawa M, Takeshita M, Kim S, Nakama M, Kawashita N, Tatsumi-Miyajima J . 6 . Genetic and genomic basis of the mismatch repair system involved in Lynch syndrome . International Journal of Clinical Oncology . 24 . 9 . 999–1011 . September 2019 . 31273487 . 10.1007/s10147-019-01494-y . 195795805 .
  16. Fishel R, Lescoe MK, Rao MR, Copeland NG, Jenkins NA, Garber J, Kane M, Kolodner R . 6 . The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer . Cell . 75 . 5 . 1027–38 . December 1993 . 8252616 . 10.1016/0092-8674(93)90546-3 . free .
  17. Yurgelun MB, Hampel H . Recent Advances in Lynch Syndrome: Diagnosis, Treatment, and Cancer Prevention . American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting . 38 . 38 . 101–109 . May 2018 . 30231390 . 10.1200/EDBK_208341 .
  18. Le S, Ansari U, Mumtaz A, Malik K, Patel P, Doyle A, Khachemoune A . Lynch Syndrome and Muir-Torre Syndrome: An update and review on the genetics, epidemiology, and management of two related disorders . Dermatology Online Journal . 23 . 11 . November 2017 . 10.5070/D32311037239 . 29447627 . free .
  19. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM, Adams MD . 6 . Mutation of a mutL homolog in hereditary colon cancer . Science . 263 . 5153 . 1625–9 . March 1994 . 8128251 . 10.1126/science.8128251 . 1994Sci...263.1625P .
  20. Miyaki M, Konishi M, Tanaka K, Kikuchi-Yanoshita R, Muraoka M, Yasuno M, Igari T, Koike M, Chiba M, Mori T . 6 . Germline mutation of MSH6 as the cause of hereditary nonpolyposis colorectal cancer . Nature Genetics . 17 . 3 . 271–2 . November 1997 . 9354786 . 10.1038/ng1197-271 . 22473295 .
  21. Nicolaides NC, Papadopoulos N, Liu B, Wei YF, Carter KC, Ruben SM, Rosen CA, Haseltine WA, Fleischmann RD, Fraser CM . 6 . Mutations of two PMS homologues in hereditary nonpolyposis colon cancer . Nature . 371 . 6492 . 75–80 . September 1994 . 8072530 . 10.1038/371075a0 . 4244907 . 1994Natur.371...75N .
  22. Lu SL, Kawabata M, Imamura T, Akiyama Y, Nomizu T, Miyazono K, Yuasa Y . HNPCC associated with germline mutation in the TGF-beta type II receptor gene . Nature Genetics . 19 . 1 . 17–8 . May 1998 . 9590282 . 10.1038/ng0598-17 . 46658147 .
  23. Ou J, Rasmussen M, Westers H, Andersen SD, Jager PO, Kooi KA, Niessen RC, Eggen BJ, Nielsen FC, Kleibeuker JH, Sijmons RH, Rasmussen LJ, Hofstra RM . 6 . Biochemical characterization of MLH3 missense mutations does not reveal an apparent role of MLH3 in Lynch syndrome . Genes, Chromosomes & Cancer . 48 . 4 . 340–50 . April 2009 . 19156873 . 10.1002/gcc.20644 . 11370/b74f7d2b-12fb-4bfc-a8c8-2d8950e81972 . 15526044 . free .
  24. Ramsoekh D, Wagner A, van Leerdam ME, Dinjens WN, Steyerberg EW, Halley DJ, Kuipers EJ, Dooijes D . 6 . A high incidence of MSH6 mutations in Amsterdam criteria II-negative families tested in a diagnostic setting . Gut . 57 . 11 . 1539–44 . November 2008 . 18625694 . 10.1136/gut.2008.156695 . 10608978 .
  25. Suchy J, Lubinski J . MSH6 syndrome . Hereditary Cancer in Clinical Practice . 6 . 2 . 103–4 . June 2008 . 19804606 . 2735474 . 10.1186/1897-4287-6-2-103 . free .
  26. Goldberg Y, Porat RM, Kedar I, Shochat C, Galinsky D, Hamburger T, Hubert A, Strul H, Kariiv R, Ben-Avi L, Savion M, Pikarsky E, Abeliovich D, Bercovich D, Lerer I, Peretz T . 6 . An Ashkenazi founder mutation in the MSH6 gene leading to HNPCC . Familial Cancer . 9 . 2 . 141–50 . June 2010 . 19851887 . 10.1007/s10689-009-9298-9 . 25479413 .
  27. Web site: Fact Sheet 33 BOWEL CANCER AND INHERITED PREDISPOSITION . dead . https://web.archive.org/web/20190228195412/http://www.genetics.edu.au/publications-and-resources/facts-sheets/fact-sheet-33-bowel-cancer-and-inherited-predisposition . 2019-02-28.
  28. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, Church JM, Dominitz JA, Johnson DA, Kaltenbach T, Levin TR, Lieberman DA, Robertson DJ, Syngal S, Rex DK . 6 . Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on colorectal cancer . Gastroenterology . 147 . 2 . 502–26 . August 2014 . 25043945 . 10.1053/j.gastro.2014.04.001 .
  29. Hildebrand. Lindsey A.. Pierce. Colin J.. Dennis. Michael. Paracha. Munizay. Maoz. Asaf. 2021-01-21. Artificial Intelligence for Histology-Based Detection of Microsatellite Instability and Prediction of Response to Immunotherapy in Colorectal Cancer. Cancers. 13. 3. 391. 10.3390/cancers13030391. 2072-6694. 7864494. 33494280. free.
  30. 6. Snowsill T, Huxley N, Hoyle M, Jones-Hughes T, Coelho H, Cooper C, Frayling I, Hyde C. September 2014. A systematic review and economic evaluation of diagnostic strategies for Lynch syndrome. Health Technology Assessment. 18. 58. 1–406. 10.3310/hta18580. 4781313. 25244061.
  31. Snowsill T, Coelho H, Huxley N, Jones-Hughes T, Briscoe S, Frayling IM, Hyde C. September 2017. Molecular testing for Lynch syndrome in people with colorectal cancer: systematic reviews and economic evaluation. Health Technology Assessment. 21. 51. 1–238. 10.3310/hta21510. 5611555. 28895526.
  32. Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D . Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer . Cancers . 11 . 10 . 1567 . October 2019 . 31618962 . 6826728 . 10.3390/cancers11101567 . free .
  33. Nouri Nojadeh . Jafar . Behrouz Sharif . Shahin . Sakhinia . Ebrahim . 2018 . Microsatellite instability in colorectal cancer . EXCLI Journal . 17 . 159–168 . en . 10.17179/EXCLI2017-948. 29743854 . 5938532 .
  34. Taieb . Julien . Svrcek . Magali . Cohen . Romain . Basile . Debora . Tougeron . David . Phelip . Jean-Marc . November 2022 . Deficient mismatch repair/microsatellite unstable colorectal cancer: Diagnosis, prognosis and treatment . European Journal of Cancer . en . 175 . 136–157 . 10.1016/j.ejca.2022.07.020. 36115290 . 252289107 . free .
  35. http://emedicine.medscape.com/article/188613-overview Hereditary Colorectal Cancer Background
  36. Monahan KJ, Bradshaw N, Dolwani S, Desouza B, Dunlop MG, East JE, Ilyas M, Kaur A, Lalloo F, Latchford A, Rutter MD, Tomlinson I, Thomas HJ, Hill J . 6 . Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland (ACPGBI)/United Kingdom Cancer Genetics Group (UKCGG) . Gut . 69 . 3 . 411–444 . March 2020 . 31780574 . 7034349 . 10.1136/gutjnl-2019-319915 .
  37. Ring KL, Garcia C, Thomas MH, Modesitt SC. November 2017. Current and future role of genetic screening in gynecologic malignancies. American Journal of Obstetrics and Gynecology. 217. 5. 512–521. 10.1016/j.ajog.2017.04.011. 28411145. 29024566.
  38. Sroczynski G, Gogollari A, Conrads-Frank A, Hallsson LR, Pashayan N, Widschwendter M, Siebert U . Cost-Effectiveness of Early Detection and Prevention Strategies for Endometrial Cancer-A Systematic Review . Cancers . 12 . 7 . 1874 . July 2020 . 32664613 . 7408795 . 10.3390/cancers12071874 . free .
  39. Web site: 2020-04-01. Medical Options CDC. 2020-12-07. www.cdc.gov. en-us.
  40. Vasen. Hans F A. Blanco. Ignacio. Aktan-Collan. Katja. Gopie. Jessica P. Alonso. Angel. Aretz. Stefan. Bernstein. Inge. Bertario. Lucio. Burn. John. Capella. Gabriel. Colas. Chrystelle. June 2013. Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts. Gut. en. 62. 6. 812–823. 10.1136/gutjnl-2012-304356. 0017-5749. 3647358. 23408351.
  41. Vasen HF, Watson P, Mecklin JP, Lynch HT . New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC . Gastroenterology . 116 . 6 . 1453–6 . June 1999 . 10348829 . 10.1016/S0016-5085(99)70510-X . free .
  42. Vindigni SM, Kaz AM . Universal Screening of Colorectal Cancers for Lynch Syndrome: Challenges and Opportunities . Digestive Diseases and Sciences . 61 . 4 . 969–76 . April 2016 . 26602911 . 10.1007/s10620-015-3964-6 . 6014333 .
  43. Bui QM, Lin D, Ho W . Approach to Lynch Syndrome for the Gastroenterologist . Digestive Diseases and Sciences . 62 . 2 . 299–304 . February 2017 . 27990589 . 10.1007/s10620-016-4346-4 . 32833106 .
  44. Stjepanovic N, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, Martinelli E; ESMO Guidelines Committee. Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow- up†. Ann Oncol. 2019 Oct 1;30(10):1558-1571. doi: 10.1093/annonc/mdz233. .
  45. Boland CR, Koi M, Chang DK, Carethers JM . The biochemical basis of microsatellite instability and abnormal immunohistochemistry and clinical behavior in Lynch syndrome: from bench to bedside . Familial Cancer . 7 . 1 . 41–52 . 2007 . 17636426 . 2847875 . 10.1007/s10689-007-9145-9 .
  46. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, Biedrzycki B, Donehower RC, Zaheer A, Fisher GA, Crocenzi TS, Lee JJ, Duffy SM, Goldberg RM, de la Chapelle A, Koshiji M, Bhaijee F, Huebner T, Hruban RH, Wood LD, Cuka N, Pardoll DM, Papadopoulos N, Kinzler KW, Zhou S, Cornish TC, Taube JM, Anders RA, Eshleman JR, Vogelstein B, Diaz LA . 6 . PD-1 Blockade in Tumors with Mismatch-Repair Deficiency . The New England Journal of Medicine . 372 . 26 . 2509–20 . June 2015 . 26028255 . 4481136 . 10.1056/NEJMoa1500596 .
  47. André . Thierry . Shiu . Kai-Keen . Kim . Tae Won . Jensen . Benny Vittrup . Jensen . Lars Henrik . Punt . Cornelis . Smith . Denis . Garcia-Carbonero . Rocio . Benavides . Manuel . Gibbs . Peter . de la Fouchardiere . Christelle . Rivera . Fernando . Elez . Elena . Bendell . Johanna . Le . Dung T. . Yoshino . Takayuki . Van Cutsem . Eric . Yang . Ping . Farooqui . Mohammed Z.H. . Marinello . Patricia . Diaz . Luis A. . Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer . New England Journal of Medicine . 3 December 2020 . 383 . 23 . 2207–2218 . 10.1056/NEJMoa2017699. 33264544 . 227259533 . free .
  48. Boland PM, Yurgelun MB, Boland CR . Recent progress in Lynch syndrome and other familial colorectal cancer syndromes . CA: A Cancer Journal for Clinicians . 68 . 3 . 217–231 . May 2018 . 29485237 . 5980692 . 10.3322/caac.21448 .
  49. Biller LH, Syngal S, Yurgelun MB . Recent advances in Lynch syndrome . Familial Cancer . 18 . 2 . 211–219 . April 2019 . 30627969 . 6450737 . 10.1007/s10689-018-00117-1 .
  50. Web site: Oncolink. https://web.archive.org/web/20110722131303/http://www.oncolink.org/types/article.cfm?c=5&s=11&ss=81&id=6979. dead. July 22, 2011. www.oncolink.org.
  51. Lynch HT, Shaw MW, Magnuson CW, Larsen AL, Krush AJ . Hereditary factors in cancer. Study of two large midwestern kindreds . Archives of Internal Medicine . 117 . 2 . 206–12 . February 1966 . 5901552 . 10.1001/archinte.117.2.206 .
  52. Bellizzi AM, Frankel WL . Colorectal cancer due to deficiency in DNA mismatch repair function: a review . Advances in Anatomic Pathology . 16 . 6 . 405–17 . November 2009 . 19851131 . 10.1097/PAP.0b013e3181bb6bdc . 25600795 .
  53. Lindor NM . Familial colorectal cancer type X: the other half of hereditary nonpolyposis colon cancer syndrome . Surgical Oncology Clinics of North America . 18 . 4 . 637–45 . October 2009 . 19793571 . 3454516 . 10.1016/j.soc.2009.07.003 .
  54. Lindor NM, Rabe K, Petersen GM, Haile R, Casey G, Baron J, Gallinger S, Bapat B, Aronson M, Hopper J, Jass J, LeMarchand L, Grove J, Potter J, Newcomb P, Terdiman JP, Conrad P, Moslein G, Goldberg R, Ziogas A, Anton-Culver H, de Andrade M, Siegmund K, Thibodeau SN, Boardman LA, Seminara D . 6 . Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X . JAMA . 293 . 16 . 1979–85 . April 2005 . 15855431 . 2933042 . 10.1001/jama.293.16.1979 .
  55. Scott RJ, McPhillips M, Meldrum CJ, Fitzgerald PE, Adams K, Spigelman AD, du Sart D, Tucker K, Kirk J . 6 . Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds . American Journal of Human Genetics . 68 . 1 . 118–127 . January 2001 . 11112663 . 1234904 . 10.1086/316942 .
  56. Gologan A, Krasinskas A, Hunt J, Thull DL, Farkas L, Sepulveda AR . Performance of the revised Bethesda guidelines for identification of colorectal carcinomas with a high level of microsatellite instability . Archives of Pathology & Laboratory Medicine . 129 . 11 . 1390–7 . November 2005 . 16253017 . 10.5858/2005-129-1390-POTRBG .
  57. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, Fishel R, Lindor NM, Burgart LJ, Hamelin R, Hamilton SR, Hiatt RA, Jass J, Lindblom A, Lynch HT, Peltomaki P, Ramsey SD, Rodriguez-Bigas MA, Vasen HF, Hawk ET, Barrett JC, Freedman AN, Srivastava S . 6 . Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability . Journal of the National Cancer Institute . 96 . 4 . 261–8 . February 2004 . 14970275 . 2933058 . 10.1093/jnci/djh034 .
  58. Lipton LR, Johnson V, Cummings C, Fisher S, Risby P, Eftekhar Sadat AT, Cranston T, Izatt L, Sasieni P, Hodgson SV, Thomas HJ, Tomlinson IP . 6 . Refining the Amsterdam Criteria and Bethesda Guidelines: testing algorithms for the prediction of mismatch repair mutation status in the familial cancer clinic . Journal of Clinical Oncology . 22 . 24 . 4934–43 . December 2004 . 15611508 . 10.1200/JCO.2004.11.084 . dead . https://archive.today/20130415031929/http://www.jco.org/cgi/pmidlookup?view=long&pmid=15611508 . 2013-04-15 .
  59. Web site: Lynch Syndrome UK. 31 March 2018.
  60. Web site: Bowel Cancer UK: Lynch Syndrome. 31 March 2018.
  61. Web site: CDC: March 22nd is National Lynch Syndrome Awareness Day!. 31 March 2018. 2018-03-20.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Hereditary nonpolyposis colorectal cancer".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.